Merck & Co Inc Overvalued by 23.5% According to GF Value Assessment
Merck & Co Inc (MRK) shares rose by 0.4% on September 29, 2026, reaching a price of $149.28. This increase continues the company's strong performance year to date, with a gain of 44.8%. Despite this growth, Merck is currently trading above its historical valuation, with a P/E ratio of 119.3x compared to its 5-year median of 20.4x.
The GF Value assessment indicates that MRK is overvalued by 23.5%, suggesting a lack of margin for safety in the current price. This high valuation could limit future upside potential, especially if earnings do not meet heightened expectations.
In terms of insider activity, there has been a negative trend with insiders selling $71.4 million worth of shares over the past 12 months without any significant buying activity. The GF Score of 81/100 signifies a strong overall rating for the company, with particularly noteworthy strengths in profitability and growth.